Paul  Sagan net worth and biography

Paul Sagan Biography and Net Worth

Director of Moderna
Paul Sagan is a senior advisor to and an Executive in Resident (XIR) at General Catalyst, a the venture capital firm, where he focuses on investments in internet software, services, and infrastructure companies. He was previously a Managing Director at the firm, with responsibility for helping to build the firm’s growth equity investing practice.

Prior to joining General Catalyst, Mr. Sagan was CEO of Akamai Technologies, a pioneer in internet content delivery, application performance and cloud security, and now one of the largest cloud services providers. He joined Akamai in October 1998 as chief operating officer, became president the following year, and was CEO from April 2005 until 2013. Mr. Sagan was elected to the Akamai Board of Directors in January 2005 and served until 2019.

Mr. Sagan is also a director of VMware, Inc. Previously, he served as a director of iRobot Corp, as well as Catalina Labs (acquired by Asurion), Dow Jones & Company (acquired by News Corp.), Digitas, Inc. (acquired by Publicis Group), EMC Corp. (acquired by Dell Technologies), and Maven Networks (acquired by Yahoo!).

Mr. Sagan began his career as a television journalist and his work was recognized with three Emmy Awards for broadcast news in New York City. Later he joined Time Warner to co-found three businesses: NY1, the 24-hour cable news network; Roadrunner, the world’s first consumer broadband service; and Pathfinder, one of the first internet advertising platforms.

President Obama appointed Mr. Sagan to the President's National Security Telecommunications Advisory Committee in 2010 and he served until 2017.

He has been a fellow of the American Academy of Arts and Sciences since 2008, and in 2009 was named Ernst & Young’s Entrepreneur of the Year in the technology category. In 1996 the World Economic Forum named Mr. Sagan a Global Leader for Tomorrow.

Mr. Sagan is a graduate of the Medill School of Journalism at Northwestern University, where he is a life trustee. He also serves as Chairman of the Board of Directors of ProPublica, and was appointed by Governor Charlie Baker to be Chairman of the Massachusetts Board of Elementary and Secondary Education from 2015 to 2019.

What is Paul Sagan's net worth?

The estimated net worth of Paul Sagan is at least $6.40 million as of November 9th, 2018. Mr. Sagan owns 59,678 shares of Moderna stock worth more than $6,399,272 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. Sagan may own. Learn More about Paul Sagan's net worth.

How do I contact Paul Sagan?

The corporate mailing address for Mr. Sagan and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on Paul Sagan's contact information.

Has Paul Sagan been buying or selling shares of Moderna?

Paul Sagan has not been actively trading shares of Moderna in the last ninety days. Most recently, Paul Sagan sold 2,250 shares of the business's stock in a transaction on Wednesday, October 13th. The shares were sold at an average price of $314.90, for a transaction totalling $708,525.00. Learn More on Paul Sagan's trading history.

Who are Moderna's active insiders?

Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.

Are insiders buying or selling shares of Moderna?

During the last year, insiders at the sold shares 56 times. They sold a total of 915,065 shares worth more than $111,561,372.06. The most recent insider tranaction occured on March, 20th when Director Noubar Afeyan sold 15,000 shares worth more than $1,535,850.00. Insiders at Moderna own 15.7% of the company. Learn More about insider trades at Moderna.

Information on this page was last updated on 3/20/2024.

Paul Sagan Insider Trading History at Moderna

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/13/2021Sell2,250$314.90$708,525.00View SEC Filing Icon  
2/14/2020Buy52,631$19.00$999,989.00View SEC Filing Icon  
See Full Table

Paul Sagan Buying and Selling Activity at Moderna

This chart shows Paul Sagan's buying and selling at Moderna by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Moderna Company Overview

Moderna logo
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $107.23
Low: $106.56
High: $112.00

50 Day Range

MA: $98.79
Low: $85.37
High: $111.98

2 Week Range

Now: $107.23
Low: $62.55
High: $163.24

Volume

2,019,002 shs

Average Volume

4,381,301 shs

Market Capitalization

$41.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6